BPTH stock icon

Bio-Path Holdings
BPTH

$2.13
2.84%
 

About: Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Employees: 10

0
Funds holding %
of 6,702 funds
Analysts bullish %
0
News positive %
of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

2.03% less ownership

Funds ownership: 4.84% [Q4 2023] → 2.8% (-2.03%) [Q1 2024]

47% less funds holding

Funds holding: 19 [Q4 2023] → 10 (-9) [Q1 2024]

72% less capital invested

Capital invested by funds: $276K [Q4 2023] → $78.6K (-$198K) [Q1 2024]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 9

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 10

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$40
1,779%
upside
Avg. target
$40
1,779%
upside
High target
$40
1,779%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Roth MKM
Philip Shen
1,779%upside
$40
Buy
Reiterated
18 Apr 2024
Roth MKM
Jonathan Aschoff
1,779%upside
$40
Buy
Maintained
27 Mar 2024

Financial journalist opinion

Based on 5 articles about BPTH published over the past 30 days